People · Operator
Named in public records as an officer, director or promoter · active 2020–2022 · Pharmaceuticals, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Celeris Therapeutics, Inc. | — | Pharmaceuticals | Seed | $3.0M | $48.7M | 2022 |
| Animal Biosciences, Inc. | — | Biotech / Pharma | Seed | $2.3M | $31.6M | 2020 |
Petr Sramek at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Petr Sramek on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Marius Swart | 1 | 1 |
| Christopher Trummer | 1 | 1 |
| Karel Kubias | 1 | 1 |
| Jakob-Ferdinand Hohenberger | 1 | 1 |
| Nicholas Sinclair | 1 | 1 |
| Jared Barlow | 1 | 1 |
| Nick Sinclair | 1 | 1 |
| Brian Malone | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.